USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOPOWERTECH
Address:
BIOPOWERTECH
4734 BLUEGRASS PKY
TUSCALOOSA, AL 35406 4040
Phone:
N/A
URL:
N/A
EIN:
260100694
DUNS:
603569331
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,312,963.00 7

Award List:

Decoy receptor 3 and liver cirrhosis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$109,681.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Liver cirrhosis is a chronic and degenerative disease that can lead to inability of the liver to perform its biochemical function thus severely affecting the quality of patients' life. Currently, liver biopsy is the gold standard in determining the presence of… More

A therapeutic potential of soluble decoy receptor 3 in sepsis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$112,572.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis remains high in intensive care units around the world but therapeutic interventions have been largely… More

Soluble Decoy Receptor 3 in Bacterial Infection and Sepsis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sepsis is a serious inflammatory reaction of the body due to bacterial infection, and the mortality rate of severe sepsis is high in intensive care units around the world. There is a great need for inventing a reliable marker to diagnose patients with sepsis in… More

Development of immunoassay to measure a novel TNF-like protein

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$115,389.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The tumor necrosis factor (TNF) family cytokines (ligands) mediate diverse immune responses via the activation of their cognate receptors expressed on the cell surface. Dysregulation and genetic defects of these cytokin es are known to be involved in various… More

A novel therapy for sepsis

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$203,439.00
Agency:
HHS
Principal Investigator:
Abstract:
Description: (Provided by Applicant) Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis remains high in intensive care units around the world but t herapeutic interventions have been largely… More

Targeting Deceoy Receptor 3 in Breast Cancer

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$335,322.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the leading cause of cancer deaths in the United States. In this year alone, approximately 40,480 women in the US are estimated to die from breast cancer. In most cases, death results from metastasis of breast cancer cells. Cancer patients with… More

Development of recombinant rhTL1A protein for cancer treatment

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$329,560.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the United States. In 2009, approximately 40,170 women in the US are estimated to die from breast ca ncer. In most cases, death results from… More